FUROXONE
LOE ApproachingNDAORALSUSPENSION
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROXONE is an oral suspension small-molecule drug approved in 1958 by Takeda. The specific indication and mechanism of action are not currently available in the product database. This legacy asset represents a mature therapeutic with established clinical use.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%) signals a transitional commercial phase requiring defensive strategies and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FUROXONE currently has zero linked job openings, reflecting its mature, stable status with minimal hiring activity. Roles on this product focus on defending market share and managing the transition to post-LOE competitive environment rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on FUROXONE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.